Rain Oncology, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2017-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.rainoncology.com
Clinical Trials
7
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
- Conditions
- Advanced Solid TumorUrothelial Carcinoma BladderMelanomaGastric CancerCDKN2ANSCLCHNSCCRenal Cell CarcinomaMesotheliomaPancreas Adenocarcinoma
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Rain Oncology Inc
- Registration Number
- NCT06090318
A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects
- Conditions
- Cardiac Repolarization
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Rain Oncology Inc
- Target Recruit Count
- 6
- Registration Number
- NCT05758818
- Locations
- 🇦🇺
Nucleus Network Melbourne, Melbourne, Victoria, Australia
Milademetan in Advanced/Metastatic Solid Tumors
- Conditions
- Solid TumorsHead and Neck CarcinomaCholangiocarcinomaSarcomaLung AdenocarcinomaOvarian CarcinomaGastric CancerBladder Urothelial CarcinomaStomach AdenocarcinomaBreast Cancer Invasive
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Rain Oncology Inc
- Target Recruit Count
- 40
- Registration Number
- NCT05012397
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Florida Cancer Specialists, Saint Petersburg, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Rain Oncology Inc
- Target Recruit Count
- 175
- Registration Number
- NCT04979442
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Sarcoma Oncology Research Center, LLC, Santa Monica, California, United States
🇺🇸UCLA Department of Medicine - Hematology/ Oncology, Santa Monica, California, United States
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
- Conditions
- EGFR Exon 20 Insertion MutationHER2-activating MutationERBB FusionNSCLC Stage IIIBNRG1 FusionNSCLC, Stage IVNSCLC, Stage IIICNSCLC, Recurrent
- Interventions
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Rain Oncology Inc
- Target Recruit Count
- 41
- Registration Number
- NCT03805841
- Locations
- 🇭🇰
RAIN-701 Study Site, Hong Kong, Hong Kong
🇺🇸Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸University of California San Francisco, Helen Diller Cancer Center, San Francisco, California, United States
- Prev
- 1
- 2
- Next